Arena Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ARNA)

$30.82 0.14 (0.46 %)
(As of 12/14/2017 01:27 PM ET)
Previous Close$30.68
Today's Range$30.60 - $31.31
52-Week Range$11.30 - $32.18
Volume328,500 shs
Average Volume535,380 shs
Market Capitalization$1.21 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.5

About Arena Pharmaceuticals (NASDAQ:ARNA)

Arena Pharmaceuticals logoArena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH). The Company's drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management. The Company's drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. The Company's programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases, and an undisclosed orphan GPCR for central nervous system (CNS) indication(s).

Receive ARNA News and Ratings via Email

Sign-up to receive the latest news and ratings for ARNA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:ARNA
CUSIP04004710
Phone+1-858-4537200

Debt

Debt-to-Equity Ratio0.27%
Current Ratio4.42%
Quick Ratio4.32%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$123.97 million
Price / Sales9.76
Cash FlowN/A
Price / CashN/A
Book Value$1.66 per share
Price / Book18.57

Profitability

Trailing EPS($0.94)
Net Income$-22,510,000.00
Net Margins-36.78%
Return on Equity-34.12%
Return on Assets-14.83%

Miscellaneous

Employees106
Outstanding Shares39,260,000

Arena Pharmaceuticals (NASDAQ:ARNA) Frequently Asked Questions

What is Arena Pharmaceuticals' stock symbol?

Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA."

When did Arena Pharmaceuticals' stock split? How did Arena Pharmaceuticals' stock split work?

Arena Pharmaceuticals's stock reverse split before market open on Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 16th 2017. An investor that had 100 shares of Arena Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

How were Arena Pharmaceuticals' earnings last quarter?

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced its earnings results on Tuesday, November, 7th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.66) by $0.01. The biopharmaceutical company had revenue of $7.95 million for the quarter, compared to analyst estimates of $5.48 million. Arena Pharmaceuticals had a negative return on equity of 34.12% and a negative net margin of 36.78%. The business's revenue for the quarter was down 58.6% compared to the same quarter last year. During the same quarter last year, the company posted ($0.05) EPS. View Arena Pharmaceuticals' Earnings History.

Where is Arena Pharmaceuticals' stock going? Where will Arena Pharmaceuticals' stock price be in 2017?

7 brokers have issued 12 month price objectives for Arena Pharmaceuticals' shares. Their predictions range from $19.00 to $60.00. On average, they anticipate Arena Pharmaceuticals' share price to reach $38.83 in the next year. View Analyst Ratings for Arena Pharmaceuticals.

What are Wall Street analysts saying about Arena Pharmaceuticals stock?

Here are some recent quotes from research analysts about Arena Pharmaceuticals stock:

  • 1. Needham & Company LLC analysts commented, "Arena mgmt hosted a conference call yesterday to provide a 2Q17 quarterly corporate update. Company announced positive results from a 61-pt Phase 2 trial of ralinepag in Pulmonary Arterial Hypertension (PAH) in Jul 2017. We await insight into FDA and EMA requirements for registration. Mgmt is not providing specific guidance, but we assume mtgs can be scheduled by YE17. Other upcoming milestones include top-line results from Phase 2 trials of etrasimod in Ulcerative Colitis (YE17) and APD-371 in pain associated with Crohn’s Disease (YE17)." (8/8/2017)
  • 2. Cantor Fitzgerald analysts commented, "We continue to view Phase 2 data as about as good as it gets. Despite facing comparisons with Phase 2 data for a drug, selexipag, that benefited from trial idiosyncrasies (subject randomization imbalances), the improvement in pulmonary vascular resistance (PVR) associated with treatment in the ralinepag Phase 2 trial (-30% vs. placebo and -20% vs. baseline) was at the high end of a range of effects noted to us by a physician knowledgeable in the care of patients with PAH and the development of therapies for it." (7/17/2017)
  • 3. According to Zacks Investment Research, "Arena received a boost with the launch of Belviq XR, a once-daily, extended-release formulation of its only marketed drug, Belviq, in October 2016. Though sales of Belviq have been lackluster so far, the company partnership agreements and efforts to improve Belviq’s performance is impressive. We are encouraged by the company’s cost reduction initiatives to streamline the organization to support its development programs. Moreover, the company’s decision to shift its priorities to its proprietary clinical-stage pipeline is also encouraging. The company recently announced positive results on its PAH candidate, ralinepeg. On the flip side, Arena’s pipeline consists of early-to-mid stage candidates that are still several years from commercialization. Moreover, competition remains intense in the obesity market which has both branded and generic players." (7/4/2017)

Who are some of Arena Pharmaceuticals' key competitors?

Who are Arena Pharmaceuticals' key executives?

Arena Pharmaceuticals' management team includes the folowing people:

  • Tina Susan Nova Ph.D., Independent Chairman of the Board (Age 63)
  • Amit D. Munshi, President, Chief Executive Officer, Director (Age 49)
  • Kevin R. Lind, Chief Financial Officer, Executive Vice President (Age 41)
  • Steven W. Spector J.D., Executive Vice President, General Counsel, Secretary (Age 52)
  • Vincent Aurentz, Executive Vice President and Chief Business Officer (Age 49)
  • Preston S. Klassen M.D., Executive Vice President - Research & Development, Chief Medical Officer (Age 48)
  • Jennifer Jarrett, Director (Age 46)
  • Scott H. Bice J.D., Independent Director (Age 74)
  • Jayson Dallas M.D., Independent Director (Age 49)
  • Oliver S. Fetzer Ph.D., Independent Director (Age 52)

Who owns Arena Pharmaceuticals stock?

Arena Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Pictet Asset Management Ltd. (1.37%), Point72 Asset Management L.P. (1.00%), JPMorgan Chase & Co. (0.80%), Macquarie Group Ltd. (0.51%), Schwab Charles Investment Management Inc. (0.46%) and Bank of New York Mellon Corp (0.43%). Company insiders that own Arena Pharmaceuticals stock include Amit Munshi and Christine Anna White. View Institutional Ownership Trends for Arena Pharmaceuticals.

Who sold Arena Pharmaceuticals stock? Who is selling Arena Pharmaceuticals stock?

Arena Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including OxFORD Asset Management LLP, GSA Capital Partners LLP, JPMorgan Chase & Co., Cornerstone Capital Management Holdings LLC. and Strs Ohio. View Insider Buying and Selling for Arena Pharmaceuticals.

Who bought Arena Pharmaceuticals stock? Who is buying Arena Pharmaceuticals stock?

Arena Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., Point72 Asset Management L.P., Macquarie Group Ltd., EAM Investors LLC, ClariVest Asset Management LLC, Pura Vida Investments LLC, Iguana Healthcare Management LLC and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Arena Pharmaceuticals.

How do I buy Arena Pharmaceuticals stock?

Shares of Arena Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Arena Pharmaceuticals' stock price today?

One share of Arena Pharmaceuticals stock can currently be purchased for approximately $30.82.

How big of a company is Arena Pharmaceuticals?

Arena Pharmaceuticals has a market capitalization of $1.21 billion and generates $123.97 million in revenue each year. The biopharmaceutical company earns $-22,510,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis. Arena Pharmaceuticals employs 106 workers across the globe.

How can I contact Arena Pharmaceuticals?

Arena Pharmaceuticals' mailing address is 6154 Nancy Ridge Dr, SAN DIEGO, CA 92121-3223, United States. The biopharmaceutical company can be reached via phone at +1-858-4537200 or via email at [email protected]


MarketBeat Community Rating for Arena Pharmaceuticals (ARNA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  182 (Vote Outperform)
Underperform Votes:  204 (Vote Underperform)
Total Votes:  386
MarketBeat's community ratings are surveys of what our community members think about Arena Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Arena Pharmaceuticals (NASDAQ:ARNA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.672.56
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $38.83$38.83$38.83$32.25
Price Target Upside: 54.78% upside54.78% upside82.75% upside138.01% upside

Arena Pharmaceuticals (NASDAQ:ARNA) Consensus Price Target History

Price Target History for Arena Pharmaceuticals (NASDAQ:ARNA)

Arena Pharmaceuticals (NASDAQ:ARNA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/25/2017Cantor FitzgeraldReiterated RatingBuy$37.00HighView Rating Details
8/8/2017Needham & Company LLCReiterated RatingHoldMediumView Rating Details
7/12/2017Wells Fargo & CompanyReiterated RatingMarket Perform$15.00 -> $19.00MediumView Rating Details
7/11/2017CitigroupBoost Price TargetBuy -> Buy$23.00 -> $37.00LowView Rating Details
7/11/2017Leerink SwannBoost Price TargetOutperform$47.00 -> $53.00HighView Rating Details
7/7/2017JMP SecuritiesUpgradeMarket Perform -> Outperform$27.00 -> $27.00HighView Rating Details
3/16/2017FBR & CoReiterated RatingOutperform$60.00MediumView Rating Details
8/10/2016Jefferies GroupReiterated RatingBuyN/AView Rating Details
8/8/2016J P Morgan Chase & CoReiterated RatingHoldN/AView Rating Details
3/2/2016Piper Jaffray CompaniesReiterated RatingBuyN/AView Rating Details
3/1/2016Royal Bank of CanadaReiterated RatingSector Perform$20.00 -> $15.00N/AView Rating Details
(Data available from 12/14/2015 forward)

Earnings

Arena Pharmaceuticals (NASDAQ:ARNA) Earnings History and Estimates Chart

Earnings by Quarter for Arena Pharmaceuticals (NASDAQ:ARNA)

Arena Pharmaceuticals (NASDAQ ARNA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($0.66)($0.65)$5.48 million$7.95 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.74)($0.77)$5.58 million$6.49 millionViewN/AView Earnings Details
5/9/2017Q1 2017($0.82)($0.90)$4.84 million$6.60 millionViewN/AView Earnings Details
3/14/2017Q4 2016($0.80)$1.60$14.12 million$85.40 millionViewN/AView Earnings Details
11/7/2016Q316($0.70)($0.50)$13.99 million$19.20 millionViewN/AView Earnings Details
8/8/2016Q216($1.00)($1.10)$10.44 million$9.50 millionViewN/AView Earnings Details
5/9/2016Q116($1.00)($0.90)$9.02 million$9.80 millionViewN/AView Earnings Details
2/29/2016Q415($1.30)($1.30)$8.26 million$7.80 millionViewN/AView Earnings Details
11/10/2015Q315($1.30)($1.10)$8.87 million$9.10 millionViewN/AView Earnings Details
8/5/2015Q215($1.40)($1.10)$10.95 million$9.18 millionViewN/AView Earnings Details
5/11/2015Q115($1.40)($1.00)$10.56 million$12.30 millionViewN/AView Earnings Details
3/2/2015Q414($1.20)($1.50)$10.36 million$9.20 millionViewN/AView Earnings Details
11/3/2014Q314($1.30)($0.50)$10.90 million$8.20 millionViewN/AView Earnings Details
8/1/2014Q2 14($1.10)($1.20)$9.81 million$12.80 millionViewN/AView Earnings Details
5/12/2014Q114($1.00)($1.20)$7.98 million$6.80 millionViewN/AView Earnings Details
2/27/2014Q413$0.20($1.10)$7.00 million$6.50 millionViewN/AView Earnings Details
11/7/2013Q313($1.20)($0.80)$5.30 million$3.60 millionViewN/AView Earnings Details
8/1/2013Q2 2013$1.50$1.80$57.30 million$68.90 millionViewN/AView Earnings Details
4/30/2013Q1 2013$1.10$0.90$50.36 million$2.37 millionViewN/AView Earnings Details
3/4/2013Q4 2012($0.30)($1.00)$21.94 million$1.94 millionViewN/AView Earnings Details
11/6/2012Q312($1.10)($0.70)$3.72 million$1.50 millionViewN/AView Earnings Details
8/9/2012($0.80)($1.20)ViewN/AView Earnings Details
11/9/2011($1.40)($1.60)ViewN/AView Earnings Details
8/9/2011($1.50)($1.60)ViewN/AView Earnings Details
5/10/2011($2.10)($3.50)ViewN/AView Earnings Details
3/11/2011($2.20)($2.30)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Arena Pharmaceuticals (NASDAQ:ARNA) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.64)($0.64)($0.64)
Q3 20171($0.69)($0.69)($0.69)
Q4 20171($0.71)($0.71)($0.71)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Arena Pharmaceuticals (NASDAQ:ARNA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Arena Pharmaceuticals (NASDAQ ARNA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.88%
Institutional Ownership Percentage: 72.85%
Insider Trades by Quarter for Arena Pharmaceuticals (NASDAQ:ARNA)
Insider Trades by Quarter for Arena Pharmaceuticals (NASDAQ:ARNA)

Arena Pharmaceuticals (NASDAQ ARNA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/12/2017Amit MunshiInsiderBuy25,000$1.19$29,750.00View SEC Filing  
4/26/2017Amit MunshiInsiderBuy50,000$1.41$70,500.00View SEC Filing  
6/13/2016Christine Anna WhiteDirectorSell18,728$1.99$37,268.72View SEC Filing  
3/30/2015Randall E WoodsDirectorSell76,268$4.49$342,443.32View SEC Filing  
3/17/2015Steven W SpectorEVPSell70,000$5.00$350,000.00View SEC Filing  
1/8/2015Steven W SpectorEVPSell45,000$6.26$281,700.00View SEC Filing  
1/7/2015William R Shanahan JrSVPSell50,000$5.49$274,500.00View SEC Filing  
7/1/2014Jack LiefCEOSell223,525$5.85$1,307,621.25View SEC Filing  
6/27/2014Donald D BelcherDirectorSell2,473$5.85$14,467.05View SEC Filing  
5/6/2014Donald BelcherDirectorSell4,176$7.00$29,232.00View SEC Filing  
4/22/2014Harry Hixson, Jr.DirectorSell36,900$6.31$232,839.00View SEC Filing  
4/14/2014Tina Susan NovaDirectorSell35,000$6.22$217,700.00View SEC Filing  
4/1/2014Donald BelcherDirectorSell1,905$6.45$12,287.25View SEC Filing  
4/1/2014William Shanahan, Jr.SVPSell60,000$6.37$382,200.00View SEC Filing  
3/4/2014Steven SpectorEVPSell25,000$7.01$175,250.00View SEC Filing  
1/17/2014Jack LiefCEOSell100,000$7.81$781,000.00View SEC Filing  
1/10/2014Dominic BehanEVPSell33,332$6.25$208,325.00View SEC Filing  
9/10/2013Dominic P BehanEVPSell200,000$6.31$1,262,000.00View SEC Filing  
9/5/2013Steven W SpectorEVPSell20,000$6.54$130,800.00View SEC Filing  
5/21/2013Craig Michael AudetSVPSell83,750$8.00$670,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Arena Pharmaceuticals (NASDAQ ARNA) News Headlines

Source:
DateHeadline
Arena Pharmaceuticals, Inc. (ARNA) Given Average Rating of "Buy" by BrokeragesArena Pharmaceuticals, Inc. (ARNA) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - December 14 at 8:42 AM
Arena Pharma Races Toward Q1 2018 Trial Results - Seeking Alpha - Seeking AlphaArena Pharma Races Toward Q1 2018 Trial Results - Seeking Alpha - Seeking Alpha
seekingalpha.com - December 12 at 5:50 AM
Here's What Pushed Arena Pharmaceuticals, Inc. Up 10.6% in NovemberHere's What Pushed Arena Pharmaceuticals, Inc. Up 10.6% in November
finance.yahoo.com - December 11 at 3:16 PM
Heres What Pushed Arena Pharmaceuticals, Inc. Up 10.6% in NovemberHere's What Pushed Arena Pharmaceuticals, Inc. Up 10.6% in November
www.fool.com - December 11 at 11:54 AM
Arena Pharmaceuticals, Inc. (ARNA) Expected to Announce Quarterly Sales of $4.43 MillionArena Pharmaceuticals, Inc. (ARNA) Expected to Announce Quarterly Sales of $4.43 Million
www.americanbankingnews.com - December 6 at 9:50 AM
Arena Pharma (ARNA) and Everest Medicines Enter Pact for ... - StreetInsider.comArena Pharma (ARNA) and Everest Medicines Enter Pact for ... - StreetInsider.com
www.streetinsider.com - December 5 at 3:17 PM
Arena Pharmaceuticals and Everest Medicines Enter into Development and Commercialization Partnership for Ralinepag and Etrasimod in ChinaArena Pharmaceuticals and Everest Medicines Enter into Development and Commercialization Partnership for Ralinepag and Etrasimod in China
finance.yahoo.com - December 5 at 3:17 PM
Zacks: Analysts Anticipate Arena Pharmaceuticals, Inc. (ARNA) to Post -$0.64 EPSZacks: Analysts Anticipate Arena Pharmaceuticals, Inc. (ARNA) to Post -$0.64 EPS
www.americanbankingnews.com - December 4 at 8:44 AM
Arena Pharmaceuticals (ARNA) Upgraded to "Strong-Buy" by BidaskClubArena Pharmaceuticals (ARNA) Upgraded to "Strong-Buy" by BidaskClub
www.americanbankingnews.com - December 2 at 3:22 PM
Market Trends Toward New Normal in Arena Pharmaceuticals, National Fuel Gas, Capitol Federal Financial, Comfort Systems, National Instruments, and Navistar International — Emerging Consolidated Expectations, Analyst RatingsMarket Trends Toward New Normal in Arena Pharmaceuticals, National Fuel Gas, Capitol Federal Financial, Comfort Systems, National Instruments, and Navistar International — Emerging Consolidated Expectations, Analyst Ratings
finance.yahoo.com - November 27 at 2:06 PM
Financial Contrast: Arena Pharmaceuticals (ARNA) and Sunesis Pharmaceuticals (SNSS)Financial Contrast: Arena Pharmaceuticals (ARNA) and Sunesis Pharmaceuticals (SNSS)
www.americanbankingnews.com - November 23 at 3:12 PM
Should You Buy Arena Pharmaceuticals Inc (ARNA) At $27.23?Should You Buy Arena Pharmaceuticals Inc (ARNA) At $27.23?
finance.yahoo.com - November 22 at 4:40 PM
Arena Pharmaceuticals, Inc. (ARNA) Given Average Recommendation of "Buy" by BrokeragesArena Pharmaceuticals, Inc. (ARNA) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - November 19 at 8:40 AM
Arena Q3: Loss But Progress On Pipeline - Seeking AlphaArena Q3: Loss But Progress On Pipeline - Seeking Alpha
seekingalpha.com - November 17 at 10:25 AM
$4.43 Million in Sales Expected for Arena Pharmaceuticals, Inc. (ARNA) This Quarter$4.43 Million in Sales Expected for Arena Pharmaceuticals, Inc. (ARNA) This Quarter
www.americanbankingnews.com - November 17 at 4:28 AM
Arena Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ARNA) : November 16, 2017Arena Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ARNA) : November 16, 2017
finance.yahoo.com - November 16 at 4:17 PM
Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ARNA-US : November 15, 2017Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ARNA-US : November 15, 2017
finance.yahoo.com - November 16 at 11:25 AM
Zacks: Analysts Expect Arena Pharmaceuticals, Inc. (ARNA) Will Announce Earnings of -$0.64 Per ShareZacks: Analysts Expect Arena Pharmaceuticals, Inc. (ARNA) Will Announce Earnings of -$0.64 Per Share
www.americanbankingnews.com - November 15 at 7:30 PM
Arena (ARNA) Completes Enrolment in Etrasimod Phase II Study ... - NasdaqArena (ARNA) Completes Enrolment in Etrasimod Phase II Study ... - Nasdaq
www.nasdaq.com - November 14 at 2:15 AM
Arena Pharma (ARNA) Completes Full Enrollment in Etrasimod Phase 2 Clinical Study for UC - StreetInsider.comArena Pharma (ARNA) Completes Full Enrollment in Etrasimod Phase 2 Clinical Study for UC - StreetInsider.com
www.streetinsider.com - November 10 at 6:53 PM
Arena Pharma (ARNA) Completes Full Enrollment in Etrasimod Phase 2 Clinical Study for UCArena Pharma (ARNA) Completes Full Enrollment in Etrasimod Phase 2 Clinical Study for UC
www.streetinsider.com - November 10 at 1:53 PM
Arena Pharmaceuticals Completes Full Enrollment in Etrasimod Phase 2 Clinical Study for Ulcerative ColitisArena Pharmaceuticals Completes Full Enrollment in Etrasimod Phase 2 Clinical Study for Ulcerative Colitis
finance.yahoo.com - November 10 at 1:53 PM
Leerink Swann Comments on Arena Pharmaceuticals, Inc.s FY2017 Earnings (ARNA)Leerink Swann Comments on Arena Pharmaceuticals, Inc.'s FY2017 Earnings (ARNA)
www.americanbankingnews.com - November 10 at 8:34 AM
ETFs with exposure to Arena Pharmaceuticals, Inc. : November 7, 2017ETFs with exposure to Arena Pharmaceuticals, Inc. : November 7, 2017
finance.yahoo.com - November 8 at 11:19 PM
Biotech Stocks on Investors Radar -- Aralez Pharma, Arena Pharma, Arrowhead Pharma, and AveXis - PR Newswire (press release)Biotech Stocks on Investors' Radar -- Aralez Pharma, Arena Pharma, Arrowhead Pharma, and AveXis - PR Newswire (press release)
www.prnewswire.com - November 8 at 6:17 PM
The Single Event That Rocketed Arena Pharmaceuticals, Inc. Higher by 10% in October - Motley FoolThe Single Event That Rocketed Arena Pharmaceuticals, Inc. Higher by 10% in October - Motley Fool
www.fool.com - November 8 at 6:17 PM
Arena Pharmaceuticals (ARNA) Q3 Loss Widens Y/Y, Sales Beat - NasdaqArena Pharmaceuticals (ARNA) Q3 Loss Widens Y/Y, Sales Beat - Nasdaq
www.nasdaq.com - November 8 at 6:17 PM
Arena Pharmaceuticals, Inc. (ARNA) Releases  Earnings Results, Beats Expectations By $0.01 EPSArena Pharmaceuticals, Inc. (ARNA) Releases Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - November 8 at 4:22 PM
Arena Pharmaceuticals (ARNA) CEO Amit Munshi on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaArena Pharmaceuticals' (ARNA) CEO Amit Munshi on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 8 at 4:46 AM
Edited Transcript of ARNA earnings conference call or presentation 7-Nov-17 9:30pm GMTEdited Transcript of ARNA earnings conference call or presentation 7-Nov-17 9:30pm GMT
finance.yahoo.com - November 8 at 4:46 AM
Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2017 Financial ResultsArena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 7 at 5:50 PM
Arena Pharmaceuticals reports 3Q lossArena Pharmaceuticals reports 3Q loss
finance.yahoo.com - November 7 at 5:49 PM
The Single Event That Rocketed Arena Pharmaceuticals, Inc. Higher by 10% in OctoberThe Single Event That Rocketed Arena Pharmaceuticals, Inc. Higher by 10% in October
www.fool.com - November 7 at 2:41 PM
Arena Pharmaceuticals to Release Third Quarter 2017 Financial Results and Provide Corporate Update on Tuesday ... - PR Newswire (press release)Arena Pharmaceuticals to Release Third Quarter 2017 Financial Results and Provide Corporate Update on Tuesday ... - PR Newswire (press release)
www.prnewswire.com - October 31 at 3:15 PM
Arena Pharmaceuticals to Present at the Credit Suisse Healthcare Conference on November 8Arena Pharmaceuticals to Present at the Credit Suisse Healthcare Conference on November 8
finance.yahoo.com - October 31 at 3:15 PM
Financial Survey: Arena Pharmaceuticals (ARNA) and Palatin Technologies (PTN)Financial Survey: Arena Pharmaceuticals (ARNA) and Palatin Technologies (PTN)
www.americanbankingnews.com - October 31 at 1:06 PM
Whats in the Cards for Arena (ARNA) This Earnings Season?What's in the Cards for Arena (ARNA) This Earnings Season?
www.nasdaq.com - October 30 at 10:00 PM
What's in the Cards for Arena (ARNA) This Earnings Season?What's in the Cards for Arena (ARNA) This Earnings Season?
finance.yahoo.com - October 30 at 9:59 PM
Arena Pharmaceuticals to Release Third Quarter 2017 Financial Results and Provide Corporate Update on Tuesday, November 7Arena Pharmaceuticals to Release Third Quarter 2017 Financial Results and Provide Corporate Update on Tuesday, November 7
finance.yahoo.com - October 30 at 4:58 PM
Arena Pharmaceuticals, Inc. (ARNA) to Release Quarterly Earnings on MondayArena Pharmaceuticals, Inc. (ARNA) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - October 30 at 8:50 AM
$4.39 Million in Sales Expected for Arena Pharmaceuticals, Inc. (ARNA) This Quarter$4.39 Million in Sales Expected for Arena Pharmaceuticals, Inc. (ARNA) This Quarter
www.americanbankingnews.com - October 28 at 8:22 AM
ETFs with exposure to Arena Pharmaceuticals, Inc. : October 27, 2017ETFs with exposure to Arena Pharmaceuticals, Inc. : October 27, 2017
finance.yahoo.com - October 27 at 6:14 PM
Arena Pharmaceuticals, Inc. (ARNA) Receives Average Rating of "Buy" from AnalystsArena Pharmaceuticals, Inc. (ARNA) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - October 25 at 8:45 AM
Arena Pharmaceuticals Announces Late Breaking Presentation of Positive Phase 2 Results with Ralinepag in Patients with Pulmonary Arterial Hypertension at the American College of Chest Physicians 2017 Annual MeetingArena Pharmaceuticals Announces Late Breaking Presentation of Positive Phase 2 Results with Ralinepag in Patients with Pulmonary Arterial Hypertension at the American College of Chest Physicians 2017 Annual Meeting
finance.yahoo.com - October 19 at 4:37 PM
Comparing Arena Pharmaceuticals (ARNA) & Advaxis (ADXS)Comparing Arena Pharmaceuticals (ARNA) & Advaxis (ADXS)
www.americanbankingnews.com - October 19 at 12:38 PM
ETFs with exposure to Arena Pharmaceuticals, Inc. : October 17, 2017ETFs with exposure to Arena Pharmaceuticals, Inc. : October 17, 2017
finance.yahoo.com - October 17 at 4:52 PM
Do This 1 Thing and Lower Your Risk for 13 Types of CancerDo This 1 Thing and Lower Your Risk for 13 Types of Cancer
finance.yahoo.com - October 15 at 3:50 PM
Arena Pharmaceuticals (ARNA) vs. The Competition Head-To-Head SurveyArena Pharmaceuticals (ARNA) vs. The Competition Head-To-Head Survey
www.americanbankingnews.com - October 13 at 8:30 PM
Heres What Lifted Arena Pharmaceuticals, Inc. Stock in September - Motley FoolHere's What Lifted Arena Pharmaceuticals, Inc. Stock in September - Motley Fool
www.fool.com - October 11 at 3:24 AM
Zacks: Brokerages Anticipate Arena Pharmaceuticals, Inc. (ARNA) Will Post Quarterly Sales of $4.39 MillionZacks: Brokerages Anticipate Arena Pharmaceuticals, Inc. (ARNA) Will Post Quarterly Sales of $4.39 Million
www.americanbankingnews.com - October 9 at 6:36 AM

SEC Filings

Arena Pharmaceuticals (NASDAQ:ARNA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Arena Pharmaceuticals (NASDAQ:ARNA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Arena Pharmaceuticals (NASDAQ ARNA) Stock Chart for Thursday, December, 14, 2017

Loading chart…

This page was last updated on 12/14/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.